JGC
ALBO

J. Goldman & Co’s Albireo Pharma Inc ALBO Stock Holding History

J. Goldman & Co’s Portfolio ALBO Stock Details ALBO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-231,278
Closed -$4.59M – 527
2022
Q2 		$4.59M Buy
+231,278
New +$6.1M 0.22% 110

Other funds holding ALBO

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CC
Chicago Capital Chicago, Illinois $3.71B AUM 19.51% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
GKIM
GW&K Investment Management Boston, Massachusetts $11.3B AUM 31.98% 1-Year Est. Return

J. Goldman & Co's ALBO Position: Q3 2022 in Review

J. Goldman & Co sold out of Albireo Pharma Inc (ALBO) in Q3 2022, closing a stake of 231,278 shares — an estimated $4.59M sold.

J. Goldman & Co first reported a position in ALBO in Q2 2022 and held it in 1 quarter. The position peaked at $4.59M in Q2 2022. 108 funds tracked by Wall St. Rank hold ALBO as of Q3 2022.

  • J. Goldman & Co reported no remaining Albireo Pharma Inc position as of Q3 2022 after selling out during the quarter.
  • J. Goldman & Co sold 231,278 Albireo Pharma Inc shares in Q3 2022, an estimated $4.59M.
  • J. Goldman & Co first reported a position in Albireo Pharma Inc in Q2 2022 and held it in 1 quarter.
  • J. Goldman & Co's Albireo Pharma Inc position peaked at $4.59M in Q2 2022.
  • 108 funds tracked by Wall St. Rank held Albireo Pharma Inc as of Q3 2022.

Based on J. Goldman & Co's 13F filing for Q3 2022, filed 14 Nov 2022.